Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2023-05-24 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团关于《2021年限制性股票激励计划》所涉限制性股票第二次解锁上市的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding the second unlocking and listing of restricted shares under a 2021 restricted stock incentive plan. It details the number of shares unlocked, the conditions met for unlocking, the approval process, and legal opinions. The content focuses on the unlocking and listing of restricted stock shares, which is a capital structure change event. It is not a full financial report, audit report, or management discussion. It is not a voting result or a general regulatory filing. The document is lengthy and detailed, not a brief announcement of a report publication. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA), as it relates to changes in share capital due to unlocking of restricted shares.
2023-05-24 Chinese
健民集团第十届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of 健民药业集团股份有限公司 regarding the resolution passed at the 9th meeting of the 10th board. It discusses the approval of the second unlocking of restricted shares under the 2021 restricted stock incentive plan, including voting results and details about the unlocking. There is no financial report, earnings data, or detailed management discussion. The document is a board resolution announcement related to stock incentive plans, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a substantive announcement of a board decision.
2023-05-24 Chinese
健民集团关于盐酸托莫西汀口服溶液获批上市的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about the approval and listing of a new pharmaceutical product (盐酸托莫西汀口服溶液) by the national drug regulatory authority. It details the drug's registration, specifications, market context, and potential impact on the company. The document does not contain financial statements, earnings data, or detailed management analysis. It is a regulatory announcement about a product approval rather than a financial report or management discussion. The document length is short (1836 characters), and it serves as a formal public disclosure of a significant company event related to product approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-24 Chinese
健民集团第十届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of 健民药业集团股份有限公司 regarding the resolution passed in their fifth meeting of the tenth supervisory board. The content focuses on the approval of the second unlocking of restricted stock under the 2021 restricted stock incentive plan. It includes voting results and mentions related disclosures on the Shanghai Stock Exchange website. The document is short (661 characters) and primarily serves as an official announcement of a board resolution related to stock incentives, not a full report or detailed financial statement. It does not contain financial data or detailed management discussion, nor is it a call transcript or legal proceeding. It is not a report publication announcement since it contains substantive content about the resolution itself. The closest fitting category is Board/Management Information (MANG), as it relates to decisions made by the supervisory board regarding management incentive plans.
2023-05-24 Chinese
健民集团董监高集中竞价减持股份计划公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding a planned share reduction by company directors and senior management through centralized bidding. It details the number of shares held by each insider, the planned reduction amounts, timing, and reasons for the reduction. The document does not contain financial statements or performance data, nor is it a report or presentation. It is a notification about insider share transactions (directors and senior management selling their own shares). This fits the definition of 'Transaction in Own Shares' (POS). The document length is under 5,000 characters and is a detailed announcement, not a brief notice or a report publication announcement. Therefore, the correct classification is POS with high confidence.
2023-05-22 Chinese
健民集团关于参加 2023 年湖北辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company about its participation in a 2023 investor online collective reception day event organized by regulatory and industry bodies. It details the date, time, format (online text interaction), participants, and how investors can submit questions. The document does not contain financial statements, earnings data, or detailed management discussion. It is a notice about an upcoming investor event rather than a report or transcript of the event itself. The document length is short (1551 characters), and it serves as an announcement of the event rather than the event content or a report. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-05-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.